[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tandem Diabetes Care, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100609174",false,"NCT07211126","The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France","RECORD-IQ","Inclusion Criteria:\n\n* Clinician-confirmed type 1 diabetes and for whom the site has initiated the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with a Dexcom G6 or G7 CGM sensor.\n* Age ≥ 6 years at enrollment.\n* Using an insulin approved for use in the pump.\n* Ability for patient or parent\u002Fguardian to respond to alerts and alarms, and to provide basic diabetes self-management.\n* Reside full-time in mainland France.\n* Have an email address and mobile phone number\n* Participant or participant's parent\u002Fguardian has read and understood the information notice and has agreed to participate in the study. This includes agreeing to :\n\n  1. use Control-IQ technology, and to continue use for at least 12 consecutive months after study enrollment.\n  2. the reuse of their clinical data including HbA1c results, obtained at most 4 months prior to enrollment, and as available according to the standard of care during the next 12 months.\n  3. complete questionnaires per the study protocol.\n\nExclusion Criteria:\n\n* A medical or other condition, or medications being taken that, in the investigator's judgement would be a safety concern for participation in the study.\n* Patients considered vulnerable under French law.","ALL","6 Years",{"count":18,"type":19},350,"ESTIMATED","OBSERVATIONAL","This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.",[23],"Diabetes Mellitus, Type 1",[25,26,27,28,29,30,31,32,33],"Control-IQ","t:slim X2 insulin pump","Control-IQ technology","DKA","severe hypoglycemia","automated insulin dosing","automated insulin delivery","quality of life","type 1 diabetes","RECRUITING","2026-04-29",{"date":37,"type":38},"2026-05-01","ACTUAL",{"date":40,"type":38},"2026-03-03",{"date":42,"type":19},"2027-12",{"name":44,"class":45},"Tandem Diabetes Care, Inc.","INDUSTRY",21,""]